Insulin 320

Drug Profile

Insulin 320

Alternative Names: I320

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 11 Sep 2017 Adverse events and pharmacodynamics data from a preclinical trial presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
  • 01 Dec 2015 Novo Nordisk completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in Germany (NCT02479022)
  • 01 Jun 2015 Phase-I clinical trials in Type-2 diabetes mellitus (In volunteers) in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top